Remember
 
 
Most Discussed Stocks  Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  UGAZ  •  APRN  •  SVMK  •  TLRY  •  GE  •  TRV  •  GLBS  •  SNAP  •  CRON  •  PXS

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithm™ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap



































































229.323M










































258.285B






























































143.205B




























































51.629B























































Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




11/12/2018: $AZN AstraZeneca: FDA accepted regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants priority review. -- Go to this Pulse Post



11/06/2018: $NKTR Nektar Therapeutics and Pfizer (PFE) announce new clinical oncology collaboration. -- Go to this Pulse Post



11/05/2018: $NVS Novartis AG will present new research showing strength of pipeline/portfolio in hematology and oncology at ASH and Breast Cancer Symposium in December. -- Go to this Pulse Post



11/02/2018: $NVS Novartis AG will present new research showing strength of pipeline/portfolio in hematology and oncology at ASH and Breast Cancer Symposium in December. -- Go to this Pulse Post



11/01/2018: $SHPG Shire plc beat by $0.05, beat on revenue; guided FY18 in-line (updated to adjust for sale of oncology franchise); reaffirmed 2020 tgt. -- Go to this Pulse Post



10/29/2018: $VRAY ViewRay announced a collaboration with GenesisCare introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients. -- Go to this Pulse Post



10/24/2018: $VAR Varian Medical signed MoU to form a strategic partnership for cancer care research in Australia. -- Go to this Pulse Post



10/22/2018: $BMY Bristol-Myers provided regulatory review update of Opdivo plus low-dose Yervoy in first-line lung cancer patients; FDA extended review period and CHMP requested additional information. -- Go to this Pulse Post



10/22/2018: $ATNX Athenex presented 'encouraging' efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients who failed previous chemotherapies in a pharmacokinetics and phase II clinical trial conducted in Taiwan. -- Go to this Pulse Post



10/22/2018: $NVS Novartis AG investigational BYL719 plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone. -- Go to this Pulse Post



10/22/2018: $LOXO Loxo Oncology announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. -- Go to this Pulse Post



10/19/2018: $NTRA Natera and Neon Therapeutics (NTGN) announce research collaboration to assess treatment response to personal cancer vaccine. -- Go to this Pulse Post



10/19/2018: $BMY Bristol-Myers provided regulatory review update of Opdivo plus low-dose Yervoy in first-line lung cancer patients; FDA extended review period and CHMP requested additional information. -- Go to this Pulse Post



10/19/2018: $INCY Incyte announced Phase 2 preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer harboring MET exon-14 skipping mutations. -- Go to this Pulse Post



10/19/2018: $MACK Merrimack Pharma discontinues Phase 2 Sherloc study of MM-121 in patients with non-small cell lung cancer due to futility. -- Go to this Pulse Post



10/18/2018: $NTRA Natera and Neon Therapeutics (NTGN) announce research collaboration to assess treatment response to personal cancer vaccine. -- Go to this Pulse Post



10/16/2018: $GH Guardant Health up 11% after lung cancer study published in JAMA Oncology shows Guardant360 outperforms tissue biopsy alone in identification of targetable mutations. -- Go to this Pulse Post



10/12/2018: $VAR Varian Medical acquired Noona Healthcare, a developer of a cloud-based, mobile service designed to capture cancer patient-reported outcomes; terms not disclosed. -- Go to this Pulse Post



10/10/2018: $VCYT Veracyte presented 'Real World' clinical utility data showing Percepta Classifier reduced invasive procedures in lung cancer diagnosis. -- Go to this Pulse Post



10/10/2018: $TYME Tyme Technologies SM-88 to be included in Pancreatic Cancer Action Network's Novel 'Precision Promise' adaptive Phase II/III pancreatic cancer trial platform. -- Go to this Pulse Post



10/09/2018: $VCYT Veracyte presented 'Real World' clinical utility data showing Percepta Classifier reduced invasive procedures in lung cancer diagnosis. -- Go to this Pulse Post



10/08/2018: $LOXO Loxo Oncology announced updated interim clinical data for LOXO-292 from the global Phase 1/2 LIBRETTO-001 trial in patients with RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. -- Go to this Pulse Post



10/03/2018: $BLRX BioLineRx to increase stake in lead oncology platform BL-8040. -- Go to this Pulse Post